Stock XLO XILIO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Xilio Therapeutics, Inc.

Equities

XLO

US98422T1007

Market Closed - Nasdaq
Other stock markets
 21:00:00 02/05/2024 BST 		5-day change 1st Jan Change
1.05 USD -2.78% Intraday chart for Xilio Therapeutics, Inc. +3.96% +90.91%
04-19 Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says MT
04-01 Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Morgan Stanley Adjusts Price Target on Xilio Therapeutics to $10 From $20, Maintains Overweight Rating
MT
Chardan Initiates Xilio Therapeutics With Buy Rating, $7 Price Target
MT
Raymond James Adjusts Price Target on Xilio Therapeutics to $13 From $31, Maintains Outperform Rating
MT
Morgan Stanley Adjusts Price Target on Xilio Therapeutics to $20 From $32, Reiterates Overweight Rating
MT
HC Wainwright Starts Xilio Therapeutics at Buy with $36 Price Target
MT
Guggenheim Starts Xilio Therapeutics at Buy With $40 Price Target
MT
Morgan Stanley Starts Xilio Therapeutics at Overweight With $32 Price Target
MT
Raymond James Starts Xilio Therapeutics at Outperform With $31 Price Target
MT
Cowen Starts Xilio Therapeutics at Outperform
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XLO Stock
  4. News Xilio Therapeutics, Inc.
  5. Analyst Reco.